Treatment targets for diabetic patients on peritoneal dialysis: Any evidence?

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Huang, Chiu Ching ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Diabetes mellitus; Glycemic control

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINO ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIALYSIS FLUID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; ICODEXTRIN; INSULIN; INSULIN GLARGINE; METFORMIN; MITIGLINIDE; ORAL ANTIDIABETIC AGENT; PHYSIONEAL; ROSIGLITAZONE; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC PATIENT; DRUG ABSORPTION; DRUG ADSORPTION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TRANSPORT; FATTY LIVER; FLUID BALANCE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIVER DYSFUNCTION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; NUTRITION; OVERALL SURVIVAL; PATIENT CARE; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; PROTEIN DEPLETION; SIDE EFFECT; TREATMENT PLANNING; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETIC NEPHROPATHIES; DIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MONITORING, PHYSIOLOGIC; PERITONEAL DIALYSIS; PROGNOSIS; SURVIVAL RATE;

EID: 35748941280     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Wu MS, Yu CC, Yang CW, Wu CH, Haung JY, Hong JJ, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997; 12:2105-10.
2. Stratton IM, Adler AI, Neil HAW, Matthews DR, Mantey SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.
3. American Diabetes Assodation. Standards of Medical Care in Diabetes - 2006. Diabetes Care 2006; 29(Suppl 1):S4-42.
4. Schwing WD, Erhard P, Newman LN, Nodge MM, Czechanski BJ, Orlin SM, et al. Assessing 24-hour blood glucose patterns in diabetic patients treated by peritoneal dialysis. Adv Perit Dial 2004; 20:213-16.
5. Stephen RL, Maxwell JG, Harrow JJ, Jacobson SC, Hanover BK. Intervention in nephropathy due to insulin-dependent diabetes mellitus (IDDM). Kidney Int 1985; 28(Suppl 17):S60-5.
6. Quellhorst E. Insutin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol 2002; 13(Suppl 1):92-6.
7. Fine A, Parry D, Ariano R, Dent W. Marked variation in peritoneal insulin absorption in peritoneal dialysis. Perit Dial Int 2000; 20:652-5.
8. 125I) insulin absorption during intermittent and continuous peritoneal dialysis. Kidney Int 1983; 23:22-8.
9. Lahtela JT, Mustonen J, Pasternack A. Comparison of intraperitoneal and subcutaneous insulin administration on insulin sensitivity and serum lipids in type 1 diabetic patients on continuous ambulatory peritoneal dialysis treatment. Clin Sci (London) 1995; 88:427-32.
10. Nevalainen P, Lahtela J, Mustonen J, Pasternack A. The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients. Nephrol Dial Transplant 1997; 12:145-50.
11. Nevalainen PI, Kallio T, Lahtela JT, Mustonen J, Pasternack AI. High peritoneal permeability predisposes to hepatic steatosis in diabetic continuous ambulatory peritoneal dialysis patients receiving intraperitoneal insutin. Perit Dial Int 2000; 20:637-42.
12. Dasgupta MK. Management of patients with type 2 diabetes on peritoneal dialysis. Adv Perit Dial 2005; 21:120-2.
13. Lin SH, Lin YF, Kuo SW, Hsu YJ, Hung YJ. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kidney Dis 2003; 42:774-80.
14. Wong TY, Szeto CC, Chow KM, Leung CB, Lam YK, Li PK. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005; 46:713-19.
15. Marshall J, Jennings P, Scott A, Fluck RJ, Mcintyre CW. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003; 64:1480-6.
16. Johnson DW, Arndt M, O'Shea A, Watt R, Hamilton J, Vincent K. Icodextrin as salvage therapyin peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2001; 2:2.
17. Gradden CW, Ahmad R, Bell GM. Peritoneal dialysis: new developments and new problems. Diabet Med 2001; 18: 360-3.
18. Hithaishi C, Lobbedez T, Padmanabhan S, Pineda ME, Oreopoulos DG. No beneficial effect of icodextrin on brood glucose control. Perit Dial Int 2004; 24:199-200.
19. Shostak A, Gotloib L. Increased peritoneal permeability to albumin in streptozotocin diabetic rats. Kidney Int 1996; 49:705-14.
20. Krediet RT, Zuyderhoudt FM, Boeschoten EW, Arisz L. Peritoneal permeability to proteins in diabetic and non-diabetic continuous ambulatory peritoneal dialysis patients. Nephron 1986; 42:133-40.
21. Coronel F, Hortal L, Naranjo P, Cruceyra A, Barrientos A. Captopril, proteinuria and peritoneal protein leakage in diabetic patients. Nephron 1989; 51:443.
22. Jones M, Hagen T, Boyle C, Vonesh E, Hamburger R, Charytan C, et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis 1998; 32: 761-9.
23. Stoenoiu MS, De Vriese AS, Brouet A, Moulin P, Feron O, Lameire N, et al. Experimental diabetes induces functional and structural changes in the peritoneum. Kidney Int 2002; 62:668-78.
24. Smit W, Esch SV, Struijk DG, Krediet RT. Free water transport in patients starting with peritoneal dialysis: a comparison between diabetic and non diabetic patients. Adv Perit Dial 2004; 20:13-17.
25. Serlie MJ, Struijk DG, De Blok K, Krediet RT. Differences in fluid and solute transport between diabetic and nondiabetic patients at the onset of CAPD. Adv Perit Dial 1997; 13:29-32.
26. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139: 105-12.
27. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43:1056-64.